Sylvester Comprehensive Cancer Center

University of Miami

Coral Gables, FL

Sorting 5 by

Accepting patients

MagnetisMM-20

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 1
  • Has results

Accepting patients

MagnetisMM-5

Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5)
Learn more
  • Bispecific Antibody
  • Phase 3

Accepting patients

SELVEDge

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/​Refractory Multiple Myeloma (SELVEDge)
Learn more
  • SINE
  • BCL-2 Inhibitor
  • Phase 1

Accepting patients

MagnetisMM-30

A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
Learn more
  • Bispecific T Cell Engager (BiTE)
  • Bispecific Antibody
  • BCMA
  • CD3
  • Phase 1
  • Has results

Not yet accepting

DURGA-4

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Learn more
  • CAR T Cell
  • CD19
  • BCMA
  • Randomization
  • Phase 3